ORTX - Got $1000? Invest in These 2 Rare Disease Stocks
Developing drugs to treat or cure rare diseases can be a lucrative line of business, as Orchard Therapeutics (NASDAQ: ORTX) and Alexion Pharmaceuticals (NASDAQ: ALXN) know. While it might seem highly limiting to target conditions that only affect a handful of patients worldwide, rare disease therapies are eligible for government programs that reduce research and development (R&D) costs while compressing the time it takes for a drug candidate to get approved. Plus, many rare diseases aren't treatable by any existing therapy, so developers can gain access to an untouched market.
The two companies I'll be discussing today are notable because they aim to exclusively treat rare illnesses. This means that they need to consistently demonstrate an immense competency in R&D across a plethora of different pathologies if they want to survive. So far, Alexion has wowed its investors with strong growth in its revenue and earnings. In contrast, Orchard is only at the start of its journey, and its appeal to investors is largely in the long-term potential of its early-stage pipeline projects. Let's investigate why both of these stocks are worth investing $1,000 in before the end of the year.
Image source: Getty Images.
For further details see:
Got $1,000? Invest in These 2 Rare Disease Stocks